Director, Publications Lead

Director, Global Publications Lead

The Director, Global Publications Lead is accountable for all scientific publications across Karyopharm. Reporting into the Head of Medical Communications/Publications, he/she will have a strategic leadership position and drive development/execution of scientific publications across Karyopharm in the Hematology/Oncology and Solid Tumor Therapeutic Areas.

This individual will lead Publications, delivering publication plans across indications and driving operational excellence. Key aspects include vendor management, systems implementation, and development of best practices to drive streamlined execution across Karyopharm. He/she will work closely with the Medical Affairs Strategy team, Program Leaders, and other cross-functional members to develop publication strategies and coordinate alignment with key cross-functional partners across core programs.

Responsibilities:

• Collaboratively lead the development and implementation of strategic publication plans for Karyopharm's core programs in Hematology/Oncology and Solid Tumor Therapeutic Areas, including global clinical studies and preclinical/translational studies.
• Lead the execution of timely and efficient publication deliverables (publication plans, abstracts and manuscripts), driving all relevant processes, including management/development of publication plans, financial tracking, and coordination with cross-functional team members while ensuring high quality and ethics.
• Oversee content and editorial support for publications.
• Serve as Karyopharm's subject matter expert on publications, providing relevant medical/scientific expertise to cross-functional teams, training on best publication practices, and strategic leadership to execute on publication strategies.
• Create specific project plans for the execution of publication tactics and liaise with cross-functional colleagues, including biostatistics, data management, clinical development, clinical operations, and others, in the tactic execution
• Review publications (eg, abstracts, posters, oral presentations, manuscripts) for adherence to overall scientific communication plan objectives and that appropriate pieces remain balanced and objective.
• Write and/or edit publications in full or in part, when needed due to resourcing and/or urgency of high-priority projects.
• Oversee and/or participate in quality checks of publications to ensure clarity and accuracy of data to source materials.
• Develop, standardize and improve publication processes while ensuring compliance and adaptation to evolving trends and guidance.
• Determine resourcing needs and engage external agencies appropriately, including contracting, onboarding, and day-to-day operations to ensure compliance and timely execution of publication plans.
• Serve as the single point of contact for internal and external stakeholders, ensuring transparent communications on all aspects of scientific and medical publications.
• Evaluate and mitigate risks related to publication planning and execution, including timing, governance, and ethics.
• Develop and maintain strong relationships with academic institutions, KOLs, journal editors, and congress organizers.
• Manage project plans efficiently and thoroughly, ensuring transparent communication with medical affairs colleagues and cross-functional colleagues as needed, escalating emerging risks as needed.
• As appropriate, operate as a sole contributor or strategic people manager in the development and execution of publication plans
• Provide guidance, oversight, training, and mentorship to direct reports, interns, and/or external consultants, as needed.

Candidate Profile & Requirements:

Qualifications:

• Advanced degree in Life Sciences required (MD, PhD, PharmD, MS).
• 5+ years of experience in publication development/management within the biotech/pharma industry
• Experience in working with/managing external vendors, including project timelines and budgets
• Oncology pharma experience required with strong therapeutic knowledge in solid and hematologic malignancies.
• Strategic mindset with ability to drive on-time tactical execution.
• Experienced in developing and refining Medical Affairs strategy.
• Strong knowledge and skills in project management with ability to prioritize/execute under tight timelines and thrive under high pressure.
• Demonstrated ability to engage collaboratively and maintain professional relationships with investigators and KOLs in relevant disease areas, journal editors, and other external stakeholders.
• Team-oriented with experience collaborating and coordinating across multiple cross-functional stakeholders.
• Flexible with ability to adapt in a fast-paced environment.
• Strong communication skills.
• Demonstrated budget and resource management skills.
• Certification as a Medical Publication Professional (CMPP) preferred.
• Working knowledge of Datavision or other publication management systems is preferred.
• Understands activities relating to planning, conduct, and analyses of clinical trials and various methods of data generation and dissemination.
• Strong knowledge and adherence to good publication practices and guidelines, including ICMJE, GPP3, and Karyopharm policies.
• Ability to travel (up to 20-30%)

At Karyopharm, base pay is one part of a competitive total rewards package that includes comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses. Actual pay is based on factors such as location, experience, skills, education, and internal equity. We maintain broad salary ranges to reflect market conditions and the specialized nature of our work. The anticipated base salary range for this position is $210 K - $250 K USD.

Our Value Proposition:

This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs.

Our lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S. We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor.

As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued.